<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034760</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-070</org_study_id>
    <nct_id>NCT02034760</nct_id>
  </id_info>
  <brief_title>Counteracting Age-related Loss of Skeletal Muscle Mass</brief_title>
  <acronym>CALM</acronym>
  <official_title>Counteracting Age-related Loss of Skeletal Muscle Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to approximately 205 (dependent on drop-out rate) healthy elderly individuals (at least 65
      years old) are recruited as subjects.

      Upon inclusion, each individual will be randomized into one of the five groups stratified
      according to gender (M/F) and 30s chair stand (&lt;16 OR ≥16). The five groups are: Heavy
      Resistance Training (N=30-35), Light Intensity Training (N=30-35), Protein Whey (N=40-50),
      Protein Collagen (N=40-50) and Carbohydrate (N=30-35). The individuals randomized into one of
      the supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded
      to the supplement content.

      Assessments will be performed at Baseline (before intervention start), and after 6 and 12
      months of intervention and again at 18 months (after 6 months of follow up).

      The primary outcome is change in quadriceps muscle cross sectional area from Baseline to 12
      months of intervention.

      The primary hypothesis is that by applying the intension-to-treat analysis, the Light
      Intensity Training group will increase quadriceps muscle cross sectional area just as much as
      the Heavy Resistance Training group. The two training groups will gain more muscle mass than
      the Protein Whey group, which will gain more than the Protein Collagen and the Carbohydrate
      groups that will loose quadriceps muscle cross sectional areas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in muscle cross sectional area</measure>
    <time_frame>Baseline, 6, 12, and 18 months</time_frame>
    <description>MRi scans of quadriceps muscle cross sectional area. The primary time interval for assessment of the primary outcome measure is from Baseline to 12 months intervention. The statistical evaluation of the primary outcome measure is done by applying a two way ANOVA test comparing groups: 1) Heavy Resistance Training vs. Light Intensity Training vs. Protein Whey and 2) Protein Whey vs. Protein Collagen vs. Carbohydrate. The statistical evaluation will be performed first as an intension-to-treat analysis and subsequently as a per-protocol analysis.
Assessments are performed at 6 months as well and at 18 months (after 6 months follow up). Changes in muscle cross sectional area will be evaluated over 6 months from Baseline to 6 months, from 6 to 12 months, and from 12 months to 18 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps muscle isometric strength</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Isometric unilateral quadriceps force and rate of force development measured in the isokinetic dynamometer device (KinCom) during knee extension at the knee angle 70 deg (with 0 degrees being fully extended).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps muscle isokinetic strength</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Unilateral knee extension (concentric) strength measured in the KinCom device at an angular velocity of 60 degrees/sec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leg extension muscle power</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Unilateral leg extension power measured in the Powerrig device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle structure and signalling</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>From muscle biopsies muscle fiber type distribution and size, capillary density, satellite cell count and activity, selected gene-expression targets and protein concentrations will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota composition.</measure>
    <time_frame>Baseline, 6 and 12 months (and 18 months on a subset of samples).</time_frame>
    <description>Molecular biology based methods incl. high throughput sequencing aided by classical, culture-based microbiological techniques as needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal metabolome.</measure>
    <time_frame>Baseline, 6 and 12 months (and 18 months on a subset of samples).</time_frame>
    <description>NMR of faecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal metabolome.</measure>
    <time_frame>Baseline, 6 and 12 months (and 18 months on a subset of samples).</time_frame>
    <description>Gas chromatography mass spectrometry (GCMS) of faecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma metabolome.</measure>
    <time_frame>Baseline, 6 and 12 months (and 18 months on a subset of samples).</time_frame>
    <description>Nuclear magnetic resonance (NMR) of plasma samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma metabolome.</measure>
    <time_frame>Baseline, 6 and 12 months (and 18 months on a subset of samples).</time_frame>
    <description>GCMS of plasma samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 30 s chair stand</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Number of stand-ups from a chair in 30 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body composition and bone mineral density</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Body composition (fat mass, lean mass and bone mass) evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning.
Bone mineral density at vertebrae L2-L4 and collum femoris evaluated by DXA-scanning.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in blood parameters and anthropometry</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Blood: HbA1c, plasma lipids, vitamin B12 and related metabolites. Anthropometry: Weight, abdominal circumference. Blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gait speed</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>400 m gait speed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in grip strength</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Isometric hand grip strength.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tendon biomechanical properties</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Measurements of tendon biomechanical properties.</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaires and interviews</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Short Form 36, Pittsburgh Sleep Scale Questionnaire, questionnaires on lifestyle, life history, supplement palatability and interviews and observations of subjects with focus on changes in lifestyle as result of intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in daily macronutrient intake</measure>
    <time_frame>Baseline, 1.5/2 and 12 months</time_frame>
    <description>3-days self-report of food and beverage intake.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in habitual activity</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Evaluated by 4 days continuous monitoring by a pedometer device (ActivPal).</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire on acceptance of supplements</measure>
    <time_frame>Weekly for first 3 months and every 3rd month until 12 months</time_frame>
    <description>Questionnaires on acceptance of supplementation</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in glucose handling measured by a OGTT</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Completion of an oral glucose tolerance test (OGTT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in vitamin B12 and related metabolite concentrations in blood</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Concentration of total B12, B12 available for cells (holoTC), and methylmalonate (MMA).</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Whey</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Collagen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two daily 30g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heavy Resistance Training</intervention_name>
    <description>Supervised Heavy Resistance Training three times weekly for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Light Intensity Training</intervention_name>
    <description>Home-based Light Intensity Training three-five times weekly for 52 weeks.</description>
    <arm_group_label>Light Intensity Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Whey</intervention_name>
    <description>Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_label>Protein Whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Collagen</intervention_name>
    <description>Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Protein Collagen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate</intervention_name>
    <description>Two daily 30g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Carbohydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, independently living

          -  Age at least 65 years

        Exclusion Criteria:

          -  Subjects dependent on help/nursing etc.

          -  Chronic medical diseases: Diabetes mellitus, clinical knee or hip osteoarthritis,
             other types of arthritis or connective tissue disorders, active cancer, renal
             diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known
             decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic
             inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia.

          -  Surgical diseases: Bone, muscle, tendon or joint injuries compromising participation
             in exercise regimens.

          -  Implanted magnetic devices incompatible with MRi-scanning.

          -  Weekly alcohol consumption &gt; 21 units (1 unit equals 4g of ethanol) for men and &gt; 14
             for women.

          -  Medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins
             in doses above 40mg/day or if combined with subjective myalgia, ACE-inhibitors,
             Angiotensin II blockers, beta-blockers, calciumantagonists, proton-pump inhibitors,
             thiazides, potassium-sparing diuretics and loop diuretics.

          -  &gt;1 hour of exercise weekly, except light activities such as stretching/gymnastics and
             bike-riding/walking as transportation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Bechshøft, Ph.d. stud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Holm, Assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kjaer, MD, Proff.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Reitelseder, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Bülow, MD PhD stud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob L. Bülow, MD</last_name>
    <phone>+45 38 35366</phone>
    <email>jacob.bulow@live.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren Reitelseder, Ph.D.</last_name>
    <phone>+45 38 35366</phone>
    <email>s.reitelseder@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispbebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Bülow, MD, Ph.d.stu</last_name>
      <phone>+45 38 35366</phone>
      <email>jacob.bulow@live.dk</email>
    </contact>
    <contact_backup>
      <last_name>Søren Reitelseder, M.Sc, Ph.d.</last_name>
      <phone>+45 38 35366</phone>
      <email>s.reitelseder@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Bülow, MD, Ph.d.stu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Holm, M.Sc., Ph.d.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Søren Reitelseder, M.Sc., Ph.d.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Lars Holm</investigator_full_name>
    <investigator_title>Ph.D. M.S.</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Ageing</keyword>
  <keyword>Protein supplementation</keyword>
  <keyword>Protein quality</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Metabolome</keyword>
  <keyword>Exercise training</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

